Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week Low - Time to Sell?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) reached a new 52-week low on Thursday . The company traded as low as $13.68 and last traded at $13.72, with a volume of 111192 shares traded. The stock had previously closed at $14.11.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Guggenheim reiterated a "buy" rating on shares of Dyne Therapeutics in a report on Friday. Royal Bank of Canada reiterated an "outperform" rating and issued a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of Dyne Therapeutics in a research note on Friday, January 10th. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Friday, January 10th. Finally, Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an "outperform" rating and a $46.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $49.91.

Dyne Therapeutics Stock Performance

The business's 50 day moving average price is $24.03 and its 200 day moving average price is $32.63. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -3.85 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Carlo Incerti sold 16,500 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares of the company's stock, valued at approximately $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,071 shares of company stock worth $606,476. Corporate insiders own 20.77% of the company's stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DYN. FMR LLC boosted its position in shares of Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company's stock worth $324,239,000 after buying an additional 3,707,734 shares during the period. RTW Investments LP lifted its stake in Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock worth $244,926,000 after acquiring an additional 431,503 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Dyne Therapeutics by 47.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock valued at $244,755,000 after acquiring an additional 2,189,339 shares during the period. RA Capital Management L.P. grew its position in Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock valued at $229,211,000 after acquiring an additional 331,940 shares in the last quarter. Finally, State Street Corp increased its stake in Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company's stock worth $130,816,000 after purchasing an additional 440,890 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.